Holen Sie sich die Stockscreener-App
51.21
2.64%
-1.39
Handel nachbörslich:
51.21
Schlusskurs vom Vortag:
$52.60
Offen:
$52.91
24-Stunden-Volumen:
2.09M
Relative Volume:
0.75
Marktkapitalisierung:
$9.79B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-21.25
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-4.07%
1M Leistung:
+4.32%
6M Leistung:
+57.13%
1J Leistung:
+90.02%
1-Tages-Spanne:
$51.03
$54.29
1-Wochen-Bereich:
$51.03
$54.60
52-Wochen-Spanne:
$21.72
$54.60
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
51.21 | 10.12B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Baird Financial Group Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Sold by Woodline Partners LP - MarketBeat
Zimmer Partners LP Raises Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
Frank Mccormick Sells 74,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby - MSN
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
BridgeBio Pharma stock price target raised to $82 from $72 at UBS - Investing.com Canada
BBIO Stock: UBS Raises Price Target Amidst Continued Buy Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Challenges Pfizer's ATTR-CM Promotion Tactics - GuruFocus
Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg - Seeking Alpha
Fred Alger Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Alliancebernstein L.P. Has $92.79 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
UBS Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
Adage Capital Partners GP L.L.C. Purchases 246,555 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Philosophy Capital Management LLC Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com
BridgeBio stock maintains Buy rating at UBS ahead of key trial data - Investing.com Canada
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $58 to $76 - 富途牛牛
Bosun Asset Management LLC Takes $412,000 Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Sold by Exome Asset Management LLC - MarketBeat
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Optimistic Buy Rating for BridgeBio Pharma: Promising ADH1 Treatment and Market Potential - TipRanks
238,168 Shares: BridgeBio Pharma's Major Employee Stock Grants Signal Growth Push in Genetic Disease Research - Stock Titan
BridgeBio Pharma stock maintains Buy rating at Jefferies on encaleret potential - Investing.com Canada
Transcript : BridgeBio Pharma, Inc.Special Call - MarketScreener
Cutter Capital Management LP Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio says new Attruby data adds to benefit in ATTR-CM - MSN
Cormorant Asset Management LP Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock By Investing.com - Investing.com South Africa
Kumar, BridgeBio Pharma CEO, sells $4.1m in BBIO stock - Investing.com
Will BridgeBio Pharma Inc. benefit from government policyPortfolio Risk Report & High Conviction Trade Alerts - classian.co.kr
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $68 - 富途牛牛
BridgeBio Pharma Inc. Price Holds Above Key Fib Level2025 Year in Review & Risk Adjusted Swing Trade Ideas - beatles.ru
BridgeBio’s Phase 2 hypoparathyroidism data; FDA clears second pig kidney trial - Endpoints News
BridgeBio Pharma (BBIO): Assessing Valuation After Strong Encaleret Data and Pipeline Advances - Yahoo Finance
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
BridgeBio Pharma’s Encaleret: Promising Developments and Potential Market Impact - TipRanks
Ieq Capital LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment By Investing.com - Investing.com Nigeria
BridgeBio’s encaleret shows promise in hypoparathyroidism treatment - Investing.com India
BridgeBio Pharma Inc. recovery potential after sell offJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
BridgeBio Pharma Reports Promising Phase 2 Results for Encaleret in Post-Surgical Hypoparathyroidism, Plans Registrational Study for 2026 - Quiver Quantitative
Encaleret Showed Parathyroid Hormone-Independent - GlobeNewswire
BridgeBio Pharma says intends to initiate registrational clinical study of Encaleret in 2026 - MarketScreener
80% Success Rate: BridgeBio's Encaleret Normalizes Calcium Levels in Breakthrough Hypoparathyroidism Study - Stock Titan
Chart based analysis of BridgeBio Pharma Inc. trendsTrade Volume Summary & High Accuracy Trade Signal Alerts - Newser
Why is BridgeBio Pharma Inc. stock going down2025 Institutional Moves & Technical Pattern Recognition Alerts - خودرو بانک
Quarry LP Makes New Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Is BridgeBio Pharma Inc. stock a top performer YTDAnalyst Downgrade & Real-Time Market Trend Scan - خودرو بانک
BridgeBio Pharma stock hits 52-week high at $52.85 By Investing.com - Investing.com Canada
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):